COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38-94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow-up of 42 days (IQR 24-96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020-22 June 2020) and second wave (23 June 2020-1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03-3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23-4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04-2.84, p = 0.04) and COVID-19 severity (severe: HR 5.66, 95% CI 2.62-12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93-36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID-related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Mina, Roberto;Bruna, Riccardo;Massaia, Massimo;Cilloni, Daniela;
2023-01-01

Abstract

COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38-94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow-up of 42 days (IQR 24-96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020-22 June 2020) and second wave (23 June 2020-1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03-3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23-4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04-2.84, p = 0.04) and COVID-19 severity (severe: HR 5.66, 95% CI 2.62-12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93-36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID-related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.
2023
41
1
128
138
https://onlinelibrary.wiley.com/doi/10.1002/hon.3092
https://doi.org/10.1002/hon.3092
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874469/
BTK inhibitors; COVID-19; SARS-CoV-2; chronic lymphocytic leukemia; outcome
Merli, Michele; Ferrarini, Isacco; Merli, Francesco; Busca, Alessandro; Mina, Roberto; Falini, Brunangelo; Bruna, Riccardo; Cairoli, Roberto; Marchetti, Monia; Romano, Alessandra; Cavo, Michele; Arcaini, Luca; Trentin, Livio; Cattaneo, Chiara; Derenzini, Enrico; Fracchiolla, Nicola Stefano; Marchesi, Francesco; Scattolin, Annamaria; Billio, Atto; Bocchia, Monica; Massaia, Massimo; Gambacorti-Passerini, Carlo; Mauro, Francesca Romana; Gentile, Massimo; Mohamed, Sara; Della Porta, Matteo Giovanni; Coviello, Elisa; Cilloni, Daniela; Visani, Giuseppe; Federici, Augusto Bramante; Tisi, Maria Chiara; Cudillo, Laura; Galimberti, Sara; Gherlinzoni, Filippo; Pagano, Livio; Guidetti, Anna; Bertù, Lorenza; Corradini, Paolo; Passamonti, Francesco; Visco, Carlo
File in questo prodotto:
File Dimensione Formato  
[Published Vsn] Merli et al - 2023- Hematol Oncol - SARS-CoV-2 infection.pdf

Accesso riservato

Descrizione: Restricted access - Published version. Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B, Bruna R, Cairoli R, Marchetti M, Romano A, Cavo M, Arcaini L, Trentin L, Cattaneo C, Derenzini E, Fracchiolla NS, Marchesi F, Scattolin A, Billio A, Bocchia M, Massaia M, Gambacorti-Passerini C, Mauro FR, Gentile M, Mohamed S, Della Porta MG, Coviello E, Cilloni D, Visani G, Federici AB, Tisi MC, Cudillo L, Galimberti S, Gherlinzoni F, Pagano L, Guidetti A, Bertù L, Corradini P, Passamonti F, Visco C. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25. PMID: 36265128; PMCID: PMC9874469. © 2022 John Wiley & Sons Ltd. Available at: https://onlinelibrary.wiley.com/doi/10.1002/hon.3092 | https://doi.org/10.1002/hon.3092 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874469/
Tipo di file: PDF EDITORIALE
Dimensione 497.26 kB
Formato Adobe PDF
497.26 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1890131
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact